Literature DB >> 12566834

Preliminary exploration of the clinical effect of bleomycin on craniopharyngiomas.

Rongcai Jiang1, Zonghui Liu, Cheng Zhu.   

Abstract

OBJECTIVE: To investigate the antitumor effect of bleomycin on craniopharyngiomas.
METHODS: A series of cystic craniopharyngiomas were randomly divided into three groups: (A) intracystic chemotherapy with bleomycin; (B) intracystic chemo-radiotherapy with bleomycin and (32)P; (C) intracystic radiotherapy with (32)P and 0.9% saline. The agents were injected into the cysts through stereotactically inserted silicone tubes. Follow-up was done for a minimum of 6 months. Outcome was based on a comparison of the volume of cysts before treatment and at follow-up. The index and lactate dehydrogenase (LD) of the cystic fluids, blood and cerebrospinal fluids and the endocrine function of these patients were determined before and after therapy.
RESULTS: 19 patients finished the whole therapeutic course: 5 from group A, 9 from group B and 5 from group C. Four tumors in group A were polycystic, and the drug was selectively injected into the largest cyst. At follow-up, the volumes of the cysts in groups A and B regressed from 92 to 0%, while the drug-free cysts enlarged. In group B, 6 cysts almost disappeared and another 3 regressed from 78 to 57%. In group C, one cyst progressed and the others shrank by different degrees, but none disappeared completely or nearly. All patients in groups A and B had fever of different degrees, which resolved spontaneously in 8-24 h. The complications in group B included hyponatremia in 1 patient, and both adephagia obesity and cerebral infarction in 2 patients (1 of whom died after 6 months). Apart from the oculomotor paralysis occurring in 1 patient, the remainder of group C had no other severe complications. Blood chemistry, liver, kidney, pituitary and endocrinal functions changed little during the course in all these 19 patients. LD and its isoenzymes from the cystic fluids, CSF and serum showed no marked change after bleomycin injection.
CONCLUSION: Bleomycin injected into cysts of craniopharyngiomas causes the tumor to shrink. When (32)P is added, the therapeutic effect seems better than treatment with either (32)P or bleomycin alone. Blood chemistry, liver, kidney and endocrine functions change little irrespective of the therapy applied. However, the combination of chemotherapy and radiotherapy may severely disturb both serum electrolytes and endocrine function. LD and its isoenzymes in the cystic fluids, CSF and serum may not change after bleomycin treatment. Copyright 2003 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12566834     DOI: 10.1159/000068014

Source DB:  PubMed          Journal:  Stereotact Funct Neurosurg        ISSN: 1011-6125            Impact factor:   1.875


  9 in total

1.  Direct percutaneous intratumoral bleomycin injection for palliative treatment of impending quadriplegia.

Authors:  Ian C Duncan; Pieter A Fourie; Albert S Alberts
Journal:  AJNR Am J Neuroradiol       Date:  2004 Jun-Jul       Impact factor: 3.825

2.  Craniopharyngiomas in children: how radical should the surgeon be?

Authors:  Juraj Steňo; Ivan Bízik; Andrej Steňo; Viktor Matejčík
Journal:  Childs Nerv Syst       Date:  2010-11-12       Impact factor: 1.475

Review 3.  Intracavitary therapeutic options in the management of cystic craniopharyngioma.

Authors:  Adrián Cáceres
Journal:  Childs Nerv Syst       Date:  2005-07-19       Impact factor: 1.475

Review 4.  Pediatric Craniopharyngiomas: A Primer for the Skull Base Surgeon.

Authors:  Christopher Salvatore Graffeo; Avital Perry; Michael J Link; David J Daniels
Journal:  J Neurol Surg B Skull Base       Date:  2018-01-19

Review 5.  Intracystic bleomycin for cystic craniopharyngiomas in children.

Authors:  Si Zhang; Yuan Fang; Bo Wen Cai; Jian Guo Xu; Chao You
Journal:  Cochrane Database Syst Rev       Date:  2016-07-14

6.  Late mortality in pediatric patients with craniopharyngioma.

Authors:  Johannes Visser; Juliette Hukin; Michael Sargent; Paul Steinbok; Karen Goddard; Chris Fryer
Journal:  J Neurooncol       Date:  2010-03-04       Impact factor: 4.130

7.  Treatment of Cystic Craniopharyngiomas: An Update.

Authors:  Federico Bianchi; Alberto Benato; Luca Massimi
Journal:  Adv Tech Stand Neurosurg       Date:  2022

8.  Trends in treatment and outcomes of pediatric craniopharyngioma, 1975-2011.

Authors:  Michal Cohen; Ute Bartels; Helen Branson; Abhaya V Kulkarni; Jill Hamilton
Journal:  Neuro Oncol       Date:  2013-03-13       Impact factor: 12.300

9.  Intracystic therapies for cystic craniopharyngioma in childhood.

Authors:  Ute Bartels; Normand Laperriere; Eric Bouffet; James Drake
Journal:  Front Endocrinol (Lausanne)       Date:  2012-03-27       Impact factor: 5.555

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.